Minerva Neurosciences (NERV) Long-Term Debt Issuances (2015)

Minerva Neurosciences (NERV) reported Long-Term Debt Issuances of $10.0 million for Q1 2015.

Minerva Neurosciences (NERV) Long-Term Debt Issuances (2015) Analysis & Trends

Minerva Neurosciences has reported Long-Term Debt Issuances for 1 years, with the latest figure at $10.0 million in Q1 2015.

  • For the quarter ending Q1 2015, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Dec 2015 stood at $10.0 million (changed N/A YoY), and the FY2015 full-year result was $10.0 million, up 431.12% from the prior year.
  • Long-Term Debt Issuances for Q1 2015 stood at $10.0 million.
  • The five-year high for Long-Term Debt Issuances was $10.0 million in Q1 2015, with the low at $10.0 million in Q1 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 2.73 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Minerva Neurosciences 197.55 Mn 197.55 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2015 10.00 Mn
Mar 31, 2015 10.00 Mn